Results 101 to 110 of about 1,354 (149)

Formulation and evaluation of stimuli-sensitive hydrogels of timolol maleate and brimonidine tartrate for the treatment of glaucoma.

Int J Pharm Investig, 2014
Dubey A, Prabhu P.
europepmc   +1 more source

Global Perspectives on Therapy for Noninfectious Conjunctival Hyperemia: A Narrative Review. [PDF]

Ophthalmol Ther
Toyos M, Chan CC, Alio JL, Chong KKL, Pek D, Doan S, Sinjab M, Hosny M, Messmer EM, Giannaccare G.   +9 more
europepmc   +1 more source

Erratum: The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum]. [PDF]

Clin Ophthalmol, 2015
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pupillometry Study of Brimonidine Tartrate 0.2% and Apraclonidine 0.5%

Journal of Clinical Pharmacology, 2011
This study investigated possible effects of brimonidine tartrate 0.2% and apraclonidine 0.5% on pupil diameter. Ten subjects between 20 and 40 years of age participated. A Colvard pupillometer (Oasis Medical) was used to measure pupil diameter. Baseline and serial measurements were obtained at 3 luminance levels (>6.4,
Patrick Hardigan, Diana Shechtman, Kimberly Reed   +2 more
exaly   +3 more sources

Allergic contact dermatitis probably due to brimonidine tartrate in eyedrops

Contact Dermatitis, 2021
Maddalena Napolitano, Gabriella Fabbrocini, Luca Potestio   +2 more
exaly   +5 more sources

Brimonidine tartrate for the treatment of glaucoma

Expert Opinion on Pharmacotherapy, 2018
Brimonidine tartrate is a commonly used eyedrop for short- and long-term lowering of intraocular pressure. Its use has been popularized due to its effects on aqueous suppression and uveoscleral outflow, as well as the suggestion of neuroprotection. Although available with alternative preservative vehicles, brimonidine is associated with high rates of ...
Daniel J, Oh, Judy L, Chen, Thasarat S, Vajaranant, Mark S, Dikopf   +3 more
openaire   +2 more sources

Side-Effect Profile of Brimonidine Tartrate in Children

Ophthalmology, 2005
To investigate brimonidine-related side effects and the efficacy of brimonidine in lowering intraocular pressure (IOP) in children with primary infantile and secondary glaucoma.Single-center, prospective, interventional, noncomparative case series.Eighty-three children (mean age, 7.84 years) met the inclusion criteria.Medical records were reviewed to ...
Sami, Al-Shahwan, Abdullah A, Al-Torbak, Shahira, Turkmani, Mamdouh, Al-Omran, Ibrahim, Al-Jadaan, Deepak P, Edward   +5 more
openaire   +2 more sources

Effect of Brimonidine Tartrate on Ocular Hemodynamics in Healthy Volunteers

Journal of Ocular Pharmacology and Therapeutics, 2001
While alpha2-adrenergic agonists, such as brimonidine tartrate, significantly reduce the intraocular pressure (IOP), the presence of vasoconstrictor postsynaptic alpha2 receptors on vascular smooth muscle raise the possibility that brimonidine could potentially compromise ocular blood flow.
Jonescu-Cuypers, Christian Paul, Harris, A, Ishii, Y, Kagemann, L, Gazozi, H J, Rotenstreich, Y, Chung, H S, Martin, B   +7 more
openaire   +2 more sources

Advances in Glaucoma Therapy: Brimonidine Tartrate

Seminars in Ophthalmology, 1997
Brimonidine, a newly approved α2-adrenoceptor agonist, is a 2-imidazoline derivative which is more highly selective for the α2-adrenoceptor than either clonidine or apraclonidine. The mechanism of action by which it lowers intraocular pressure (IOP) involves a decrease in aqueous humor production and an increase in aqueous humor outflow through the ...
David S. Greenfield, Jeffrey M. Liebmann, Robert Ritch   +2 more
openaire   +1 more source

Development and Evaluation of Novel Polymeric Nanoparticles of Brimonidine Tartrate

Current Drug Delivery, 2010
Micro and nanoparticulate carriers have been in focus in ophthalmic drug delivery with the objective of improving bioavailability, drug targeting and reducing pulse entry of the drug in ocular cul de sac. Polymeric nanoparticles for ocular purpose have potential in reducing the pulse entry and frequency of dosing, thus improving patient compliance.
Kavita H, Singh, Ujwala A, Shinde
openaire   +2 more sources